247 related articles for article (PubMed ID: 15598950)
1. Extended rituximab therapy in Waldenström's macroglobulinemia.
Treon SP; Emmanouilides C; Kimby E; Kelliher A; Preffer F; Branagan AR; Anderson KC; Frankel SR;
Ann Oncol; 2005 Jan; 16(1):132-8. PubMed ID: 15598950
[TBL] [Abstract][Full Text] [Related]
2. Expression of complement inhibitors CD46, CD55, and CD59 on tumor cells does not predict clinical outcome after rituximab treatment in follicular non-Hodgkin lymphoma.
Weng WK; Levy R
Blood; 2001 Sep; 98(5):1352-7. PubMed ID: 11520782
[TBL] [Abstract][Full Text] [Related]
3. Paradoxical increases in serum IgM and viscosity levels following rituximab in Waldenstrom's macroglobulinemia.
Treon SP; Branagan AR; Hunter Z; Santos D; Tournhilac O; Anderson KC
Ann Oncol; 2004 Oct; 15(10):1481-3. PubMed ID: 15367407
[TBL] [Abstract][Full Text] [Related]
4. CD20-directed antibody-mediated immunotherapy induces responses and facilitates hematologic recovery in patients with Waldenstrom's macroglobulinemia.
Treon SP; Agus TB; Link B; Rodrigues G; Molina A; Lacy MQ; Fisher DC; Emmanouilides C; Richards AI; Clark B; Lucas MS; Schlossman R; Schenkein D; Lin B; Kimby E; Anderson KC; Byrd JC
J Immunother; 2001; 24(3):272-9. PubMed ID: 11394506
[TBL] [Abstract][Full Text] [Related]
5. Treatment of Waldenström's macroglobulinemia with rituximab.
Dimopoulos MA; Zervas C; Zomas A; Kiamouris C; Viniou NA; Grigoraki V; Karkantaris C; Mitsouli C; Gika D; Christakis J; Anagnostopoulos N
J Clin Oncol; 2002 May; 20(9):2327-33. PubMed ID: 11981004
[TBL] [Abstract][Full Text] [Related]
6. Extended rituximab therapy for previously untreated patients with Waldenström's macroglobulinemia.
Dimopoulos MA; Zervas C; Zomas A; Hamilos G; Gika D; Efstathiou E; Panayiotidis P; Vervessou E; Anagnostopoulos N; Christakis J
Clin Lymphoma; 2002 Dec; 3(3):163-6. PubMed ID: 12521393
[TBL] [Abstract][Full Text] [Related]
7. CHOP plus rituximab therapy in Waldenstrom's macroglobulinemia.
Treon SP; Hunter Z; Barnagan AR
Clin Lymphoma; 2005 Mar; 5(4):273-7. PubMed ID: 15794864
[TBL] [Abstract][Full Text] [Related]
8. Soluble CD27 is a faithful marker of disease burden and is unaffected by the rituximab-induced IgM flare, as well as by plasmapheresis, in patients with Waldenström's macroglobulinemia.
Ciccarelli BT; Yang G; Hatjiharissi E; Ioakimidis L; Patterson CJ; Manning RJ; Xu L; Liu X; Tseng H; Gong P; Sun J; Zhou Y; Treon SP
Clin Lymphoma Myeloma; 2009 Mar; 9(1):56-8. PubMed ID: 19362974
[TBL] [Abstract][Full Text] [Related]
9. CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59.
Golay J; Lazzari M; Facchinetti V; Bernasconi S; Borleri G; Barbui T; Rambaldi A; Introna M
Blood; 2001 Dec; 98(12):3383-9. PubMed ID: 11719378
[TBL] [Abstract][Full Text] [Related]
10. Expression of complement regulatory proteins: CD46, CD55, and CD59 and response to rituximab in patients with CD20+ non-Hodgkin's lymphoma.
Dzietczenia J; Wróbel T; Mazur G; Poreba R; Jaźwiec B; Kuliczkowski K
Med Oncol; 2010 Sep; 27(3):743-6. PubMed ID: 19662541
[TBL] [Abstract][Full Text] [Related]
11. Rituximab (anti-CD20) therapy of B-cell lymphomas: direct complement killing is superior to cellular effector mechanisms.
Harjunpää A; Junnikkala S; Meri S
Scand J Immunol; 2000 Jun; 51(6):634-41. PubMed ID: 10849376
[TBL] [Abstract][Full Text] [Related]
12. Pentostatin/cyclophosphamide with or without rituximab: an effective regimen for patients with Waldenstrom's macroglobulinemia/lymphoplasmacytic lymphoma.
Hensel M; Villalobos M; Kornacker M; Krasniqi F; Ho AD
Clin Lymphoma Myeloma; 2005 Sep; 6(2):131-5. PubMed ID: 16231851
[TBL] [Abstract][Full Text] [Related]
13. Lenalidomide and rituximab in Waldenstrom's macroglobulinemia.
Treon SP; Soumerai JD; Branagan AR; Hunter ZR; Patterson CJ; Ioakimidis L; Chu L; Musto P; Baron AD; Nunnink JC; Kash JJ; Terjanian TO; Hyman PM; Nawfel EL; Sharon DJ; Munshi NC; Anderson KC
Clin Cancer Res; 2009 Jan; 15(1):355-60. PubMed ID: 19118065
[TBL] [Abstract][Full Text] [Related]
14. Rituximab therapy in Waldenstrom's macroglobulinemia: preliminary evidence of clinical activity.
Byrd JC; White CA; Link B; Lucas MS; Velasquez WS; Rosenberg J; Grillo-López AJ
Ann Oncol; 1999 Dec; 10(12):1525-7. PubMed ID: 10643548
[TBL] [Abstract][Full Text] [Related]
15. Once-weekly ofatumumab in untreated or relapsed Waldenström's macroglobulinaemia: an open-label, single-arm, phase 2 study.
Furman RR; Eradat HA; DiRienzo CG; Hofmeister CC; Hayman SR; Leonard JP; Coleman M; Advani R; Chanan-Khan A; Switzky J; Liao QM; Shah D; Jewell RC; Lisby S; Lin TS
Lancet Haematol; 2017 Jan; 4(1):e24-e34. PubMed ID: 27914971
[TBL] [Abstract][Full Text] [Related]
16. Clinical value of minor responses after 4 doses of rituximab in Waldenström macroglobulinaemia: a follow-up of the Eastern Cooperative Oncology Group E3A98 trial.
Gertz MA; Abonour R; Heffner LT; Greipp PR; Uno H; Rajkumar SV
Br J Haematol; 2009 Dec; 147(5):677-80. PubMed ID: 19751237
[TBL] [Abstract][Full Text] [Related]
17. Myelopathy from Waldenström's macroglobulinemia: improvement after Rituximab therapy.
Liberato B; Riethmuller A; Comenzo RL; Lis E; Raizer JJ
J Neurooncol; 2003 Jun; 63(2):207-11. PubMed ID: 12825826
[TBL] [Abstract][Full Text] [Related]
18. [Effective treatment with rituximab in two patients with Waldenström macroglobulinemia].
Yoshimi A; Arai S; Iijima K; Iki S; Usuki K; Urabe A
Rinsho Ketsueki; 2005 Oct; 46(10):1109-13. PubMed ID: 16440772
[TBL] [Abstract][Full Text] [Related]
19. Thalidomide and rituximab in Waldenstrom macroglobulinemia.
Treon SP; Soumerai JD; Branagan AR; Hunter ZR; Patterson CJ; Ioakimidis L; Briccetti FM; Pasmantier M; Zimbler H; Cooper RB; Moore M; Hill J; Rauch A; Garbo L; Chu L; Chua C; Nantel SH; Lovett DR; Boedeker H; Sonneborn H; Howard J; Musto P; Ciccarelli BT; Hatjiharissi E; Anderson KC
Blood; 2008 Dec; 112(12):4452-7. PubMed ID: 18713945
[TBL] [Abstract][Full Text] [Related]
20. Complement-binding proteins are strongly expressed by human preimplantation blastocysts and cumulus cells as well as gametes.
Taylor CT; Johnson PM
Mol Hum Reprod; 1996 Jan; 2(1):52-9. PubMed ID: 9238658
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
